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Abstract
Background: Malignant mesothelioma is a locally aggressive and highly lethal neoplasm of pleural, peritoneal and
pericardial mesothelial cells without successful therapy. Previously, we reported that Quercetin in combination with
Cisplatin inhibits cell proliferation and activates caspase-9 and -3 enzymes in different malignant mesothelioma cell
lines. Moreover, Quercetin + Cisplatin lead to accumulation of both SPC111 and SPC212 cell lines in S phase.
Methods: In present work, 84 genes involved in cell growth and proliferation have analysed by using RT2-PCR array
system and protein profile of mitogen activated protein kinase (MAPK) family proteins investigated by western blots.
Results: Our results showed that Quercetin and Quercetin + Cisplatin modulated gene expression of cyclins, cyclin
dependent kinases and cyclin dependent kinases inhibitors. In addition genes involved in JNK, p38 and MAPK/ERK
pathways were up regulated. Moreover, while p38 and JNK phosphorylations were increased, ERK phosphorylations
were decreased after using Quercetin + Cisplatin.
Conclusion: This research has clarified our previous results and detailed mechanism of anti-carcinogenic potential of
Quercetin alone and incombination with Cisplatin on malignant mesothelioma cells.
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Background
Malignant mesothelioma (MM) is a neoplastic prolif-
eration that develops from pleural, peritoneal or
rarely pericardial mesothelial cells [1]. Long time ex-
posure to asbestos and/or erionite and genetic predis-
position are known to cause MM [2]. Platinum drug
‘Cisplatin’ (CIS) is conventionally employed against to
MM [1]. Indeed, the combination therapies with CIS
& Pemetrexed or Raltitrexed are currently used to
treat MM patients [3]. However, it is required to im-
prove alternative strategies or drugs since resistance
of cancer cells to CIS therapy [4]. Quercetin (QU) is
a plant derived flavonoid exhibiting anti-proliferative,
growth suppressing and apoptotic effects in several
cell lines [5–7]. QU induced anti-proliferative effect
associated with alterations in the signal transduction
pathways including MAPKs, PI3K/AKT and EGFR [7–
10]. The enhanced anti-proliferative effect of QU with
CIS was reported in cervix, leukaemia and hepatocel-
lular carcinoma cells [11–13]. Additionally, we
formerly reported that QU + CIS treatment of differ-
ent MM cell lines (SPC111 and SPC212) caused a de-
crease in proliferation and an increase in apoptosis
[14]. However, SPC212 cells were found to be much
more sensitive to QU + CIS. Therefore, in the present
work, 84 genes involved in cell proliferation and
growth are evaluated in QU, CIS and/or QU + CIS
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QU and CIS (Sigma-Aldrich) stock solutions were pre-
pared in dimethylsulfoxide (DMSO, cell culture tested;
Sigma-Aldrich) and stored at −20 °C. The chemicals were
diluted 100X in fresh media before each experiment. The
anti-proliferative activity of single and combined chemical
treatments were assessed in a monolayer culture condition
by plating cells in 100 mm petri dishes.
Cell line and culture
A human MM cell line SPC212 was used as a model sys-
tem. SPC212 was derived from a tumour with mixed hist-
ology of female patient, which was obtained as a gift from
The Institute of Histology and General Embryology,
University of Fribourg, Switzerland. Cells were cultured
in RPMI, supplemented with 10 % FBS, L-glutamine
(2 mM), 2 % NaHCO3 (Sigma-Aldrich), and 1 % penicil-
lin/streptomycin (Invitrogen-Gibco) in a humidified at-
mosphere containing 5 % CO2 at 37 °C. Cells were treated
with single and/or combined concentrations of QU
(50 μM) and CIS (5 μg/mL) according to our previous
findings from MTS assay [14].
RNA isolation and RT2-PCR
Total RNA was extracted from 2 × 106 cultured SPC212
cells exposed to 50 μM QU, 5 μg/mL CIS and in com-
bination or only % 0.01 DMSO as a solvent control for
48 h using RNeasy Mini Kit and treated with RNase-free
DNase (SABiosciences, Qiagen) according to the manu-
facture’s protocol. Before the total RNA extractions, cell
lysate was homogenized by using QIA shredder
homogenizer (SABiosciences, Qiagen) and then reverse
transcription of 2 μg of total RNA into cDNA was per-
formed using the RT2 First Strand Kit (SABiosciences,
Qiagen). cDNAs were kept on ice and then immediately
used for RT-PCR array or were stored at −20 °C until
using the further processes. The RT2-PCR assays were
performed on Stratagene Mx3005P using the MAP
Kinase Signalling Pathway RT2 profiler PCR Array
(#PAHS-061Z; SABiosciences) and RT2 SYBR Green
Master Mix (SABiosciences, Qiagen) according to the
manufacture’s protocol. Thermal profile was set as seg-
ment 1 for denaturation (1 cycle): at 95 °C for 10 min;
segment 2 for annealing/extension (40 cycle): at 95 °C
for 15 s, at 60 °C for 1 min; segment 3 for melting curve
(1 cycle): at 95 °C for 1 min, at 55 °C for 30 s, at 95 °C
for 30 s. The mRNA expression levels of 84 MAP Kinase
Signalling Pathway-related genes in the QU and in com-
bination treated cells were compared to control cells,
and then evaluated according to the ΔΔCt method using
Data Analysis web-based software (www.SABiosciences.-
com/pcrarraydataanalysis.php). Data were normalized to
housekeeping genes included in a RT2PCR Array plate
(ACTB; β-actin and RPLP0; ribosomal protein large P0).
Several experiments were performed and only the one
with p-values above 0.90 for all genes after analysis using
Data Analysis web-base software was considered.
SDS PAGE/Western blotting
Cells were cultured as 2 × 106 cells per 100-mm-
dish incubated for 24 h, and then serum starvation is per-
formed for the next 24 h. Later, medium was replaced
with serum-free medium and cells were incubated for 12,
24 and 48 h with or without chemicals, as 5 μg/mL CIS
and 50 μM QU and in combination. Then, whole-cells
were obtained from PBS suspension and passed through
syringes for 15 times to explode cells. Lysates were col-
lected within 200 μL of lysis buffer and 1 % protease phos-
phatase inhibitor cocktail (Thermo Scientific). Protein
concentrations of samples were determined by Pierce
BCA Protein Assay Kit. 15 μg of total protein from each
sample were separated on a 12 % SDS-PAGE and trans-
ferred to PVDF membranes (Hybond-P Amersham, GE
Healthcare). Membranes were blocked 1 h in TBS-T con-
taining 5 % non-fat dried milk that followed by application
of antibodies for p-ERK and ERK (Santa Cruz Bio), p-p38,
p38, p-JNK, JNK and Actin (Cell signalling) and then re-
spective secondary antibodies conjugated with horseradish
peroxidase. Thermo, Pierce ECL kit was used to develop
membranes to detect chemiluminescence which is de-
tected via ChemiDoc XRS (Bio-Rad) imaging system.
Results
The effects of QU + CIS on cell cycle and MAPK pathway
genes
To investigate whether QU + CIS changed gene expres-
sions of SPC212 cells, we exposed cells with QU + CIS
(50 μM+ 5 μg/mL) and QU (50 μM). The RT2-PCR
array revealed that compared to untreated cells expres-
sion of cylin dependent kinase inhibitor (CDI) genes
[CDKN1A (p21), CDKN1B (p27), CDKN1C (p57),
CDKN2A (p16) and CDKN2B (p15),] were up regulated
in QU + CIS and QU treated cells respectively.
Interestingly, cyclins [CCNA (cyclin A1), CCNA2 (cyc-
lin A2), CCNB1 (cyclin B1), CCNB2 (cyclin B2), CCND1
(cyclin D1), CCND2 (cyclin D1), CCND3 (cyclin D3) and
CCNE1 (cyclin E1)] and cylin dependent kinase2 (CDK2)
gene expressions were also elevated greater than two-
fold in QU + CIS treated cells (Fig. 1).
We next examined the alteration of JNK/SAPKs and
p38MAPK pathway genes after drug applications. As
seen in Fig. 2, treatment with QU + CIS resulted in in-
creased expression of DLK, MAP3K4 (MEKK4),
MAP2K4 (MEK4), CDC42 and MAPK8IP2/JIP1 (inter-
acts with JNK1) genes on two-fold or more. Moreover,
transcription factors (TFs) activated through JNK path-
way including ATF2 (Creb-2), NFATC4 (NFAT3) and
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CREBBP (transcriptional co-activator) were also up reg-
ulated comparing to untreated cells. Although any up
regulation in the expression of genes involved in JNK
pathway, arise gene expressions of p38 pathway
(MAP2K6/MEK6 and MAPK11/p38β) were observed in
QU treated cells.
Similarly, genes involved in classical MAPK pathway were
explored after treatment either with QU or QU+CIS
(Fig. 3). Genes including ARAF, GRB-2, MAPK3/ERK1 and
KSR-1, FOS, ELK-1, E2F1 and EGR1 were up regulated
two-fold or more in single QU treatments. Unlikely, expres-
sion of EGFR, BRAF, MOS, MAP2K1/MEK1, LAMTOR3/
MP1, FOS and ETS2 genes were raised in combined
treatments. In addition, genes activated in response to cell
protection and/or survival including HSPA5/HSP70 and
CHUCK/IKKα were up regulated in combine treatments.
Interestingly, only two genes were down regulated after ex-
posure to QU+CIS including MAPK interacting kinase
(MNK1) and tumour suppressor protein,TP53 (p53).
The effects of QU + CIS on MAPK pathway proteins
Finally, expression and activation levels of ERK, JNK and
p38 proteins were evaluated after treatments in 48 h. As
shown in Fig. 4, phosphorylation level of ERKs (p44 and
p42) was decreased, but JNKs (p54 and p46) and p38
were increased in first 24 h and then, decreased (Fig. 4).
Fig. 1 mRNA levels of cell cycle regulators. CDI, cyclin and cyclin dependent kinase(CDK) expressions in SPC212 cells treated with QU and
QU + CIS. Two-fold or more differences compared to control cells were evaluated by RT-PCR array. Group 1: DMSO Control versus Quercetin;
Group 2: DMSO control versus Quercetin + Cisplatin
Fig. 2 mRNA levels of JNK/SAPK and p38MAPK pathway members. Cells treated with 50 μM QU and 50 μM QU + 5 μg/ml CIS. Two-fold or more
differences compared to control cells were evaluated by RT2-PCR array Group 1: DMSO Control versus Quercetin; Group 2: DMSO control
versus Quercetin + Cisplatin
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Discussion
Development of effective inhibitors for proliferating can-
cerous cells is one of the most important issues in cancer
treatment. Since development of drug resistance, cancer
cells have been subjected to exposure chemicals espe-
cially in combinations [3]. It is well-known that the pro-
gression of cell cycle is regulated by Cylins, CDKs and
CDIs in mammalian cells. Two distinct families of CDIs
are classifying as p21/p27 and p16/p18. While the p21
family members are potent inhibitors to almost all CDK
enzymes, the p16 family members are specific inhibitors
to CDK4 and CDK6 only [15]. Earlier, we revealed that
QU + CIS application caused accumulation of high per-
cent of cells in S phase at 48 h [14]. In here, up regulated
gene expression of CDIs (CDKN1A, CDKN1B, CDKN2A
and CDKN2B after QU + CIS exposure supports our pre-
vious result and identifies which genes act on cell cycle
arrest mechanism of SPC212 cells. Unexpectedly, raised
expression CDK2, G1/S, S and G2/M cyclin genes
propose resistance of cells to CIS. CDK2 is known to
play transition from G1 to S phase through S phase to
G2 phase [16]. Since CDK2 is associated with CIS resist-
ance [17], it is an important candidate target for cancer
therapy. Therefore, it may recommend integrating
specific CDK2 inhibitor into QU + CIS mix for future
work. Single QU treatments in SPC212 cells caused up
regulation of CDKN1C, MEK6 and MAPK11 gene ex-
pressions. Recently, it is reported that environmental
stress transiently activates p38MAPK, which in turn,
phosphorylates p57 leading an increased affinity to
CDK2-CyclinE/A activity and subsequent G1 arrest [18].
Thus, this can be also the case in QU treated SPC212
cells. Besides, raised MAPK gene expressions may indicate
maintenance of this effect.
Tanida et al. demonstrated that CIS induced toxic ef-
fects via MAPKs [19]. Zhang et al. and others [20–22]
reported that ELK-1, Rac and CDC42 activated
p38MAPK. In addition, Fan et al. and others [23–26]
showed that DLK and MEK also activated both p38 and
JNK pathways. Similarly, along with our results we as-
sume that CDC42, DLK, MEKK4, MEK4 and JNK
interacting protein (JIP1) up regulations implies involve-
ment of p38 and JNK pathways in QU + CIS exposed
SPC212 cells. Besides, up regulations of TF genes includ-
ing ATF-2, NFAT and CREBBP (co-activator) encouraged
Fig. 3 mRNA levels of MAPK and survival pathway members. Two-fold or more differences compared to control cells were evaluated by RT2-PCR
array. Group 1: DMSO Control versus Quercetin; Group 2: DMSOcontrol versus Quercetin + Cisplatin
Fig. 4 Phosphorylation and total protein levels of MAPKs. Cells were
treated with 5 μg/ml CIS, 50 μM QU or both for a series of time and
15 μg their proteins were analysed by Western Blotting as described
in material methods. The experiments were repeated at least three
times with similar results
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contribution of p38 and JNK pathways. Moreover, as it
is demonstrated in Fig. 4, increased phosphorylation of
JNK and p38 proteins indicated activation of both path-
ways in response to combined treatments. Thornton
et al. [27] reported that p38 negatively regulates cell
cycle by several mechanisms through down regulation of
cylins, up regulation of CDI and modulation of p53. Our
results propose that QU and QU + CIS mediate S phase
arrest through up regulation of CDI, which may be asso-
ciated with gene and protein up regulations of p38 in
SPC212 cells. Beyond cell cycle arrest, activation of p38
and JNK pathways are also often correlated with stress-
related apoptosis [28]. Initially we found that exposure
to cells with QU + CIS caused enzymatic Caspase- 3 and
caspase- 9 activations [14]. Therefore, another possibility
that QU + CIS generated apoptosis of SPC212 cells as a
result of activation of JNK and p38 pathways.
It is well documented that activated p53 triggers a
number of signalling pathways leading to cell cycle
arrest, DNA repair, apoptosis and senescence [29].
Surprisingly, p53 gene expression was down regulated
in QU + CIS treated cells. Tafolla et al. [30] exposed
that activation of JNK pathway lead to negative regu-
lation of p53. Thus, we thought that negative regula-
tion of p53 after QU + CIS treatment may related to
JNK pathway activations in SPC212 cells. However, it
is also possible that p38 and JNK signalling mediated
apoptosis was not depended on p53 activity [31]. In-
deed, analysed initial apoptotic gene expressions pat-
terns signified that TP73 (p73) gene was up regulated
in the combine treatments (data not shown). In
addition, QU mediated mitochondrial apoptosis was re-
ported in the absence of p53 but in the presence of TP63
(p63) and p73 [32] and CIS activated p73-dependent apop-
tosis was informed by Yoshida et al. [33]. Subsequently, our
results indicate existence of a p53-independent apoptosis in
response to QU+CIS treatments.
Mainly, activation of MAPK/ERK pathway is associ-
ated with proliferation and survival of cells. On the con-
trary, increasing evidence shows that MAPK activation
contributes to apoptosis in some cell types. Conflicting
results exists on the consequences of CIS initiated
MAPK activations. Persons et al. [34] demonstrated that
CIS induced MAPK1/2 activation protects cells from
cytotoxicity of CIS. However, Wang et al. [35] indicated
that CIS creates MAPK initiated apoptosis. Similar
contradictory results also reported on QU’s activities.
Some researchers showed that apoptotic contribution of
QU requires inactivation of the MAPK pathway and
others declare opposite effects [7]. Our gene analysis
demonstrated that although some MAPK pathway genes
were up regulated, the protein phoshorylations were
down regulated in QU and QU + CIS treated cells. In
combine treatments another up regulated expressions
was on HSP70/HSPA5 and IKKα/CHUCK genes. HSP70
occasionally was expressed in response to unfolded pro-
tein stress [36] and IKKα/CHUCK was induced by DNA
damages or activation of NF-kappa-β pathway [37]. These
results propose that QU+CIS induced stress dependent
survival signals leading to increased MAPK gene activa-
tion. At the same time, the cytostatic and/or apoptotic
capacities of agents decreased post-transcriptional phos-
phorylation of SPC212 cells. In addition, we observed
down regulation of MNK1 gene after QU+CIS treat-
ments. Activation of MNKs (MNK1 and MNK2) was indi-
cated in drug resistance and negative regulation of
apoptosis via modulating transcription of anti-apoptotic
genes [38, 39]. Down regulation of MNK1 gene may sug-
gest subsequent down regulation of anti-apoptotic genes
leading to apoptosis of SPC212 cells.
Conclusions
In conclusion, QU + CIS induced S phase arrest that is
regulated by almost all CDIs in SPC212 cells. The sup-
pressed cell proliferation arrested cell cycle and triggered
cell death of SPC212 cells depends on three MAPK
pathway activations. Although survival /resistance path-
ways activated by QU + CIS treatments, SPC212 cells
were undergone to apoptosis which probably implles
JNK and p38 MAPK pathway involvment
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